AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 95 filers reported holding AKERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $112 | +107.4% | 10,600 | -5.4% | 0.01% | +37.5% |
| Q2 2023 | $54 | -19.4% | 11,200 | -41.4% | 0.01% | +14.3% |
| Q1 2023 | $67 | -78.4% | 19,100 | -61.7% | 0.01% | -73.1% |
| Q4 2022 | $310 | -99.7% | 49,900 | +10.6% | 0.03% | +333.3% |
| Q3 2022 | $98,000 | +263.0% | 45,100 | +1704.0% | 0.01% | +500.0% |
| Q1 2021 | $27,000 | +12.5% | 2,500 | +56.2% | 0.00% | -50.0% |
| Q3 2020 | $24,000 | +9.1% | 1,600 | +60.0% | 0.00% | +100.0% |
| Q2 2020 | $22,000 | +266.7% | 1,000 | +233.3% | 0.00% | – |
| Q1 2020 | $6,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |